Aurobindo Pharma Ltd

Aurobindo Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1436.1, up 1.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.75% on the day, quoting at 24195.15. The Sensex is at 77763.49, down 0.96%. Aurobindo Pharma Ltd has risen around 12.06% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has risen around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 13.11 lakh shares today, compared to the daily average of 17.53 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 1436.1, up 1.33% on the day. Aurobindo Pharma Ltd is up 14.18% in last one year as compared to a 0.21% drop in NIFTY and a 4.48% drop in the Nifty Pharma index.The PE of the stock is 38.5 based on TTM earnings ending December 25.

The product is indicated for the temporary relief of cough caused by minor throat and bronchial irritation, such as that associated with the common cold or inhaled irritants. It also helps suppress the urge to cough, aiding sleep. The approved formulation is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Delsym extended-release oral suspension, 30 mg/5 mL, marketed by RB Health (US) LLC. Aurobindo Pharma said the product will be manufactured at Unit IV of APL Healthcare, its wholly owned subsidiary, and is expected to be launched in Q2 FY27. According to Nielsen data for the 12 months ended February 2026, the product has an estimated market size of $138 million. With this approval, the company now has a total of 580 ANDA approvals from the USFDA, including 557 final approvals and 23 tentative approvals. The official announcement was made on 17 April 2026, after market hours. Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 7.6% rise in consolidated net profit to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. The counter shed 0.62% to Rs 1,377 on the BSE.

The approved product is bioequivalent and therapeutically equivalent to the reference-listed drug, Ravicti, marketed by Horizon Therapeutics U.S. Holding LLC. The company said the product will be manufactured at its Unit-III facility and will be launched immediately. According to IQVIA MAT data, the approved drug has an estimated market size of $50.2 million for the 12 months ending February 2026. With this approval, Aurobindo Pharma's total ANDA approvals from the USFDA stand at 579, including 556 final approvals and 23 tentative approvals. Glycerol phenylbutyrate oral liquid is indicated as a nitrogen-binding agent for the chronic management of patients with urea cycle disorders (UCDs) who cannot be adequately managed through dietary protein restriction and amino acid supplementation alone. Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 7.6% rise in consolidated net profit to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. The counter rose 0.09% to Rs 1,387.30 on the BSE.

Aurobindo Pharma announced the receipt of the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Ravicti Oral Liquid 1.1 grams per mL, of Horizon Therapeutics U.S. Holding LLC. The product will be manufactured by Unit-III of the Company and will be launched immediately. The approved product has an estimated market size of US$ 50.2 million for the twelve months ending February 2026, according to IQVIA MAT. Aurobindo Pharma now has a total of 579 ANDA approvals (556 final approvals and 23 tentative approvals) from USFDA. Glycerol Phenylbutyrate Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

The approved product is a generic version of AstraZeneca's Xigduo XR and will be manufactured at the company's Unit-IV facility of APL Healthcare, a wholly owned subsidiary, with immediate market launch planned. The combination therapy is indicated as an adjunct to diet and exercise to improve glycaemic control in adults where treatment with both medicines is appropriate. According to IQVIA data, the product has an estimated US market size of $514 million for the twelve months ending February 2026. Aurobindo is eligible for 180 days of shared generic exclusivity as one of the first applicants. As of March 31, 2026, the company had a total of 579 ANDA approvals from the USFDA, including 554 final approvals and 25 tentative approvals. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. Shares of Aurobindo Pharma shed 0.76% to close at Rs 1,329.60 on the BSE.

Aurobindo Pharma announced that the final approval is received from the US Food & Drug Administration (USFDA) to manufacture and market Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/ 500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xigduo XR Tablets, 5 mg/ 500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg, of AstraZeneca AB. These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately.

Aurobindo Pharma announced that the final approval is received from the US Food & Drug Administration (USFDA) to manufacture and market Dapagliflozin Tablets, 5 mg and 10 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB. These products will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company and will be launched immediately.

The company plans to repurchase up to 54,23,728 fully paid-up equity shares, representing about 0.93% of its total paid-up equity capital. The buyback size corresponds to 3.93% and 2.62% of the company's aggregate paid-up equity share capital and free reserves based on its standalone and consolidated financial statements as at March 2025, respectively. The buyback will be undertaken on a proportionate basis from all eligible shareholders, including promoters and members of the promoter group, in accordance with applicable regulations. As per the latest available shareholding data, promoters and promoter group entities hold a 51.82% stake in the company. The board has fixed 17 April 2026 as the record date to determine the eligibility of shareholders entitled to participate in the buyback. The company also constituted a buyback committee to oversee and execute the process. It noted that the buyback price may be increased and the number of shares reduced, subject to regulatory provisions, without altering the overall buyback size. Further details, including timelines and the offer process, will be released in due course as part of the public announcement and letter of offer. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25. Shares of Aurobindo Pharma were currently down 0.26% to Rs 1,332.45.

The board of Aurobindo Pharma at its meeting held on 06 April 2026 has approved the transfer of the Company's domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement (BTA) to Auropharm (previously known as Auro Pharma), a wholly owned subsidiary of the Company. It is in line with the Company's strategy in further streamlining and accelerating Company's domestic business for faster growth.

Aurobindo Pharma has fixed 17 April 2026 as record date for the purpose of determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback.